Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10

Benzinga Newsdesk www.benzinga.com Positive 76.7%

Neg 0% Neu 0% Pos 76.7%

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.